Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Merck
Mallinckrodt
Dow
Johnson and Johnson

Last Updated: December 8, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TOFACITINIB CITRATE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Tofacitinib Citrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02197455 ↗ Tofacitnib for the Treatment of Alopecia Areata and Variants Completed Yale University Phase 2 2014-07-01 The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.
NCT02312882 ↗ Tofacitinib for the Treatment of Alopecia Areata and Its Variants Completed Stanford University N/A 2014-12-01 The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.
NCT03002649 ↗ Study of Tofacitinib in Refractory Dermatomyositis Completed Pfizer Phase 1 2017-01-01 The purpose of this study is to obtain preliminary data regarding the safety and efficacy of Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory dermatomyositis.
NCT03002649 ↗ Study of Tofacitinib in Refractory Dermatomyositis Completed Johns Hopkins University Phase 1 2017-01-01 The purpose of this study is to obtain preliminary data regarding the safety and efficacy of Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory dermatomyositis.
NCT04114461 ↗ Study to Evaluate HL-TOF Tab. 5 mg Compared With XelJanz Tab. in Healthy Volunteers Completed Hanlim Pharm. Co., Ltd. Phase 1 2019-11-06 To evaluate the safety and pharmacokinetics of HL-TOF tab. 5 mg compared with those of XelJanz tab. in healthy volunteers
NCT04468425 ↗ Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study Recruiting TWi Biotechnology, Inc. Phase 1 2020-10-14 This is a Phase 1, single center, open-label, fixed sequence, two-period pharmacokinetic (PK) study to evaluate the safety and relative systemic bioavailability of topical and oral tofacitinib formulations in approximately 14 healthy subjects. Participants will receive a single oral dose of tofacitinib 5 mg tablet in Period 1 of the study followed by a 7-day washout period. In Period 2, participants will receive repeat administration of Tofacitinib Citrate Topical Gel 3.2% BID for 14 days.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tofacitinib Citrate

Condition Name

Condition Name for Tofacitinib Citrate
Intervention Trials
Cutaneous Lupus Erythematosus 1
Dermatomyositis 1
Healthy Subjects 1
Healthy Volunteers 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tofacitinib Citrate
Intervention Trials
Alopecia Areata 2
Alopecia 2
Lupus Erythematosus, Cutaneous 1
Dermatomyositis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tofacitinib Citrate

Trials by Country

Trials by Country for Tofacitinib Citrate
Location Trials
United States 4
Korea, Republic of 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tofacitinib Citrate
Location Trials
Michigan 1
Maryland 1
California 1
Connecticut 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tofacitinib Citrate

Clinical Trial Phase

Clinical Trial Phase for Tofacitinib Citrate
Clinical Trial Phase Trials
Phase 2 1
Phase 1 4
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tofacitinib Citrate
Clinical Trial Phase Trials
Completed 4
Not yet recruiting 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tofacitinib Citrate

Sponsor Name

Sponsor Name for Tofacitinib Citrate
Sponsor Trials
TWi Biotechnology, Inc. 1
Autoimmunity Centers of Excellence 1
Rho Federal Systems Division, Inc. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tofacitinib Citrate
Sponsor Trials
Other 4
Industry 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Johnson and Johnson
Dow
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.